Acute myeloid leukemia (AML): Disease risk but not remission status determines transplant outcomes – new ASAP long-term results
2025-10-06
(Press-News.org) The selection of patients for allo-HSCT and the best approach to bridging patients to transplantation is continuously discussed by experts. The first results of the ASAP study (ASAP standing for “as soon as possible”), published in 2024, have already attracted considerable attention [2]. ASAP questions existing treatment standards for AML and was the first randomized controlled trial to compare remission induction with salvage chemotherapy prior to allo-HSCT – which represents the current standard of care (SOC) – against an alternative approach of immediate transplantation after intensified conditioning combined with non-intensive disease control strategies such as less aggressive chemotherapy or simple monitoring of leukemic proliferation. These two groups are referred to as the SOC arm and the alternative treatment arm, respectively.
ASAP: Transplantation as soon as possible
The now published long-term analysis [1] supports the initial results of the ASAP trial [2]. The findings suggest, that a transplantation as soon as possible yields comparable treatment outcomes as remission induction – with shorter hospital stays and reduced exposure to chemotherapy [1]. “The results question the international standard of leukemia treatment. We no longer need to give all patients a very aggressive chemotherapy to reduce the tumor burden ahead of transplantation when regimens with good anti-leukemic activity are used for conditioning on the days prior to stem cell transplantation,” says Prof. Dr. Johannes Schetelig, coauthor of the study.
The results were based on a median follow-up of 61 months in the patient cohort: The induction of remission in the SOC arm (5-year OS: 47.5%) compared to immediate transplantation in the alternative treatment arm (5-year OS: 46.1%) showed no overall survival (OS) advantage in AML patients, which were poorly responsive to initial treatment or with untreated relapse [1]. Since non-inferiority could not be demonstrated formally, immediate transplantation will not replace the common SOC but can be considered more often today [1]. One argument in favor of proceeding directly to transplantation without remission induction is that patients who received intensive salvage chemotherapy in the SOC arm spent one month longer in hospital and experienced more adverse events [1].
Age and AML genetics are the most important risk factors influencing survival
The long-term follow-up of ASAP additionally analyzed treatment success according to risk classification and genetic subgroups. Both age and AML genetics were identified as the most important baseline risk factors influencing survival. AML genetics were classified according to the ELN 2022 criteria [1].
The overall survival probabilities at 5 years (5-year OS) from randomization in the different risk groups independent from treatment arm were [1]:
66% with favorable risk AML,
53% with intermediate risk AML, and
34% for adverse risk AML.
When both the ELN risk and the treatment were taken into account, the 3-year overall survival was 77% for patients with favorable/intermediate AML with watchful waiting in the alternative treatment arm (N = 49) versus 66% for patients transplanted with complete remission in the SOC arm in the same risk group (N = 49) [1].
An important step towards precision medicine in transplantation
“In summary, it can be concluded that survival after allo-HSCT in AML patients is less influenced by remission induction or bridging strategies and more influenced by intrinsic disease biology,” concludes Prof. Schetelig. Interestingly, reducing the pre-transplant leukemia burden did not translate into improved survival when intensive cytotoxic regimens were used, challenging a common assumption in treatment planning [1].
The uncertain benefits of inducing remission prior to allo-HSCT are in contrast to the fundamental impact of AML genetics. Favorable risk AML was associated with higher survival rates compared to adverse risk AML. These findings are consistent with previous reports on the prognostic impact of the ELN 2022 classification in patients undergoing allogeneic stem cell transplantation [1]. “But the data of the ASAP trial also demonstrate that tolerable novel bridging therapies and posttransplant maintenance for more personalized strategies are urgently warranted, especially for adverse risk AML, to improve outcomes after allo-HSCT,” summarizes Prof. Dr. Johannes Schetelig. “These findings open the door for future research to identify specific AML subgroups – a key step towards precision medicine in transplantation.”
DKMS fosters scientific progress
The ASAP study, initiated and realized by DKMS, reflects the focus on various areas of innovation to fight blood cancer from every angle. "It is our declared goal to improve the survival and healing chances for patients with blood cancer by investing in research to enhance current treatments and explore innovative approaches,” highlights Dr. Elke Neujahr, Global CEO DKMS.
As an international non-profit organization, DKMS places special importance on scientific questions that are not driven by commercial interests. This includes research that helps to enable access to holistic treatments worldwide, or that critically examines the use of current standard treatments. DKMS partners with medical experts across continents to foster scientific progress, funds research projects on an international level, conducts clinical trials, and honors outstanding scientific work with the DKMS Mechtild Harf Science Award. With the DKMS John Hansen Research Grant the organization supports actively young scientists with innovative approaches in the field of blood cancer (current application deadline: November 20, 2025). Find out more about all scientific information at DKMS Professionals’ Platform.
1 Stelljes, M. et. al. Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial. Blood 2025 Jul 30:blood.2025028730. doi: 10.1182/blood.2025028730 Online ahead of print.
2 Stelljes, M. et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024;11(5):e324-e335. doi: 10.1016/S2352-3026(24)00065-6
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-10-06
In a recent study published in Cell Metabolism, a collaborative research team led by Chen-Yu Zhang, Xi Chen, and Di-Jun Chen from Nanjing University, together with Tao Zhang from Nanjing Medical University, reported groundbreaking findings in their paper entitled “Paternal exercise confers endurance capacity to offspring through sperm microRNAs.” This research provides the first evidence that sperm microRNAs act as carriers of epigenetic information, enabling the intergenerational transmission of paternal ...
2025-10-06
New artificial intelligence-generated images that appear to be one thing, but something else entirely when rotated, are helping scientists test the human mind.
The work by Johns Hopkins University perception researchers addresses a longstanding need for uniform stimuli to rigorously study how people mentally process visual information.
“These images are really important because we can use them to study all sorts of effects that scientists previously thought were nearly impossible to study in isolation—everything from size to animacy to emotion,” said ...
2025-10-06
About The Study: Inhaler-related emissions in the U.S. have increased over the past decade. Policymakers and regulators seeking to reduce emissions should identify targeted solutions aimed at shifting utilization to currently marketed dry powder and soft mist inhalers while facilitating the entry of newer, affordable metered-dose products containing propellants with low global warming potential.
Corresponding Author: To contact the corresponding author, William B. Feldman, MD, DPhil, MPH, email wfeldman@mednet.ucla.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.16524)
Editor’s ...
2025-10-06
Inhalers are the frontline treatment for asthma and COPD, but they come with a steep environmental cost, according to a new UCLA Health study — the largest to date quantifying inhaler-related emissions in the United States.
Researchers found that inhalers have generated over 2 million metric tons of carbon emissions annually over the past decade, equivalent to the emissions of roughly 530,000 gas-powered cars on the road each year.
The study, published in JAMA, analyzed emissions from the three types of inhalers approved for asthma or COPD from 2014 to 2024. It found that metered-dose inhalers were the most ...
2025-10-06
About The Study: In this cohort study, implementation of the sickest patients first (SIPS) surgical handover system (introduction, situation, background, assessment, recommendation; prioritize; summarize) was associated with improvements in handover quality, patient physiology, and staff perceptions of safety without prolonging handover meetings.
Corresponding Author: To contact the corresponding author, Jessica M. Ryan, MB, email jessicaryan@rcsi.com.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.38896)
Editor’s ...
2025-10-06
About The Study: In this prospective cohort study of young adults, unfavorable patterns of cardiovascular health (CVH) change through young adulthood were associated with marked elevations in risk for incident cardiovascular disease (CVD). These data suggest that achieving and maintaining high CVH throughout young adulthood through strategies of primordial prevention are important for prevention of later-life CVD.
Corresponding author: To contact the corresponding author, Donald M. Lloyd-Jones, M.D., ...
2025-10-06
About The Study: In this cross-sectional study, nurses’ subjective workload and shift-level staffing ratios exerted direct effects on reliable care delivery. High subjective workload and staffing ratios greater than 2 infants per nurse should be targets for workload reduction in neonatal intensive care units.
Corresponding Author: To contact the corresponding author, Heather L. Tubbs-Cooley, Ph.D., email tubbscooley.1@osu.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi: 10.1001/jamapediatrics.2025.3647)
Editor’s ...
2025-10-06
The remote work debate often focuses only on leadership or the employee, but according to a new doctoral dissertation from the University of Vaasa, Finland, the prerequisites for success are found in a broader context. Johanna Jansson's research in the field of human resource management reveals that successful remote work is built on three foundations: overall organisational design, the supervisor-subordinate relationship, and the employee's own role. When these three foundations are in balance, both company ...
2025-10-06
WASHINGTON — Researchers have created a chip-based device that can split phonons — tiny packets of mechanical vibration that can carry information in quantum systems. By filling a key gap, this device could help connect various quantum devices via phonons, paving the way for advanced computing and secure quantum communication.
“Phonons can serve as on-chip quantum messages that connect very different quantum systems, enabling hybrid networks and new ways to process quantum information in a compact, scalable format,” said research team ...
2025-10-06
HOUSTON (Oct. 6, 2025) – Researchers at Texas Children’s Neurological Research Institute (NRI) and Baylor College of Medicine have developed a powerful new tool within the Genome Aggregation Database (gnomAD) to sharpen the accuracy of genetic testing – a breakthrough with direct implications for patient diagnoses and care worldwide.
The work, published in Nature Communications, applies a method called local ancestry inference (LAI), which breaks the genome into ancestry-specific segments to provide more accurate insights into genetic differences.
“This research updates our genomic resources to better reflect the ...
LAST 30 PRESS RELEASES:
[Press-News.org] Acute myeloid leukemia (AML): Disease risk but not remission status determines transplant outcomes – new ASAP long-term results